Literature DB >> 33589636

Discrete SARS-CoV-2 antibody titers track with functional humoral stability.

Yannic C Bartsch1, Stephanie Fischinger1,2, Sameed M Siddiqui3,4, Zhilin Chen1, Jingyou Yu1,5, Makda Gebre1,5, Caroline Atyeo1, Matthew J Gorman1, Alex Lee Zhu1, Jaewon Kang1, John S Burke1, Matthew Slein1, Matthew J Gluck6,7, Samuel Beger6, Yiyuan Hu6, Justin Rhee6, Eric Petersen6, Benjamin Mormann6, Michael de St Aubin8, Mohammad A Hasdianda9, Guruprasad Jambaulikar9, Edward W Boyer9, Pardis C Sabeti4,10,11,12, Dan H Barouch1,5,12, Boris D Julg1, Elon R Musk6, Anil S Menon13, Douglas A Lauffenburger14, Eric J Nilles15, Galit Alter16,17.   

Abstract

Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only serve as a surrogate of protection. Instead, the ability of vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked to protection. While evidence has begun to point to persisting antibody responses among SARS-CoV-2 infected individuals, cases of re-infection have begun to emerge, calling the protective nature of humoral immunity against this highly infectious pathogen into question. Using a community-based surveillance study, we aimed to define the relationship between titers and functional antibody activity to SARS-CoV-2 over time. Here we report significant heterogeneity, but limited decay, across antibody titers amongst 120 identified seroconverters, most of whom had asymptomatic infection. Notably, neutralization, Fc-function, and SARS-CoV-2 specific T cell responses were only observed in subjects that elicited RBD-specific antibody titers above a threshold. The findings point to a switch-like relationship between observed antibody titer and function, where a distinct threshold of activity-defined by the level of antibodies-is required to elicit vigorous humoral and cellular response. This response activity level may be essential for durable protection, potentially explaining why re-infections occur with SARS-CoV-2 and other common coronaviruses.

Entities:  

Year:  2021        PMID: 33589636     DOI: 10.1038/s41467-021-21336-8

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  39 in total

1.  SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.

Authors:  Emilie Finch; Rachel Lowe; Stephanie Fischinger; Michael de St Aubin; Sameed M Siddiqui; Diana Dayal; Michael A Loesche; Justin Rhee; Samuel Beger; Yiyuan Hu; Matthew J Gluck; Benjamin Mormann; Mohammad A Hasdianda; Elon R Musk; Galit Alter; Anil S Menon; Eric J Nilles; Adam J Kucharski
Journal:  PLoS Biol       Date:  2022-02-10       Impact factor: 8.029

2. 

Authors:  Kevin Yau; Christopher T Chan; Kento T Abe; Yidi Jiang; Mohammad Atiquzzaman; Sarah I Mullin; Ellen Shadowitz; Lisa Liu; Ema Kostadinovic; Tatjana Sukovic; Anny Gonzalez; Margaret E McGrath-Chong; Matthew J Oliver; Jeffrey Perl; Jerome A Leis; Shelly Bolotin; Vanessa Tran; Adeera Levin; Peter G Blake; Karen Colwill; Anne-Claude Gingras; Michelle A Hladunewich
Journal:  CMAJ       Date:  2022-05-30       Impact factor: 16.859

3.  Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation.

Authors:  Dieter Mielke; Sherry Stanfield-Oakley; Shalini Jha; Taylor Keyes; Adam Zalaquett; Brooke Dunn; Nicole Rodgers; Thomas Oguin; Greg D Sempowski; Raquel A Binder; Gregory C Gray; Shelly Karuna; Lawrence Corey; John Hural; Georgia D Tomaras; Justin Pollara; Guido Ferrari
Journal:  Cytometry A       Date:  2022-04-01       Impact factor: 4.714

4.  Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.

Authors:  Steven M Brunelli; Scott Sibbel; Steph Karpinski; Gilbert Marlowe; Adam G Walker; Jeffrey Giullian; David Van Wyck; Tara Kelley; Rachael Lazar; Meredith L Zywno; Jeffrey J Connaire; Amy Young; Francesca Tentori
Journal:  J Am Soc Nephrol       Date:  2022-02-08       Impact factor: 14.978

5.  Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Authors:  Donal T Skelly; Adam C Harding; Eleanor Barnes; Miles W Carroll; William S James; Javier Gilbert-Jaramillo; Michael L Knight; Stephanie Longet; Anthony Brown; Sandra Adele; Emily Adland; Helen Brown; Tom Tipton; Lizzie Stafford; Alexander J Mentzer; Síle A Johnson; Ali Amini; Tiong Kit Tan; Lisa Schimanski; Kuan-Ying A Huang; Pramila Rijal; John Frater; Philip Goulder; Christopher P Conlon; Katie Jeffery; Christina Dold; Andrew J Pollard; Alex Sigal; Tulio de Oliveira; Alain R Townsend; Paul Klenerman; Susanna J Dunachie
Journal:  Nat Commun       Date:  2021-08-17       Impact factor: 14.919

6.  SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.

Authors:  Fatima Amanat; Mahima Thapa; Tinting Lei; Shaza M Sayed Ahmed; Daniel C Adelsberg; Juan Manuel Carreño; Shirin Strohmeier; Aaron J Schmitz; Sarah Zafar; Julian Q Zhou; Willemijn Rijnink; Hala Alshammary; Nicholas Borcherding; Ana Gonzalez Reiche; Komal Srivastava; Emilia Mia Sordillo; Harm van Bakel; Jackson S Turner; Goran Bajic; Viviana Simon; Ali H Ellebedy; Florian Krammer
Journal:  Cell       Date:  2021-06-08       Impact factor: 66.850

7.  Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study.

Authors:  Jens Van Praet; Marijke Reynders; Dirk De Bacquer; Liesbeth Viaene; Melanie K Schoutteten; Rogier Caluwé; Peter Doubel; Line Heylen; Annelies V De Bel; Bruno Van Vlem; Deborah Steensels; An S De Vriese
Journal:  J Am Soc Nephrol       Date:  2021-09-29       Impact factor: 10.121

8.  Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers.

Authors:  Ayşen Bayram; Hadiye Demirbakan; Pınar Günel Karadeniz; Merve Erdoğan; Ipek Koçer
Journal:  J Med Virol       Date:  2021-05-31       Impact factor: 20.693

9.  Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.

Authors:  María Velasco; Maria Isabel Galán; Maria Luisa Casas; Elia Pérez-Fernández; Diana Martínez-Ponce; Beatriz González-Piñeiro; Virgilio Castilla; Carlos Guijarro
Journal:  Open Forum Infect Dis       Date:  2021-06-04       Impact factor: 3.835

10.  An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.

Authors:  Ahmed O Hassan; Swathi Shrihari; Matthew J Gorman; Baoling Ying; Dansu Yuan; Saravanan Raju; Rita E Chen; Igor P Dmitriev; Elena Kashentseva; Lucas J Adams; Colin Mann; Meredith E Davis-Gardner; Mehul S Suthar; Pei-Yong Shi; Erica Ollmann Saphire; Daved H Fremont; David T Curiel; Galit Alter; Michael S Diamond
Journal:  Cell Rep       Date:  2021-07-10       Impact factor: 9.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.